Post sponsored by

MIL OSI Translation. Region: Russian Federation –

Any adult citizen who has not previously been vaccinated against coronavirus can take part in them.

Sputnik V vaccine, developed by Moscow scientists from the Institute named after N.F. Gamalea has proven to be effective and safe. Almost 600 thousand Muscovites have already been vaccinated. Many countries of the world became interested in the drug, wrote in Sergey Sobyanin on his blog… The Mayor of Moscow also announced that several large-scale studies will be carried out in the near future regarding vaccination against COVID-19.

This week, an epidemiological study of immunity stability after coronavirus vaccination began in the capital. Two thousand people who got their first vaccine three to six months ago will take an antibody test every month (from February to August). Thus, specialists will see the dynamics of changes that will occur in each of the study participants nine to ten months or even a year after vaccination. The study will make it possible to understand whether re-vaccination against COVID-19 will be required on the eve of the next epidemiological fall-winter season.

In addition, on the basis of the children’s city clinical hospital named after Z.A. Bashlyaeva will conduct three phases of a clinical study of the Sputnik V vaccine for adolescents aged 14 to 18 years. Based on the results, it will be possible to decide on the inclusion of this group in the vaccination program.

“We are also exploring new ways to protect against coronavirus. Specialists have developed a nasal form of “Sputnik V”, which forms immunity in the nasopharynx area. This drug is not a substitute for complete vaccination, but it can be useful as an additional form of protection. All three phases of clinical trials of the drug are also planned to be conducted in Moscow, ”wrote Sergei Sobyanin.

The Mayor of Moscow announced that international clinical trials of the Sputnik Light vaccine will begin on February 18.

“The new drug, developed at the Gamaleya Institute, is designed to eliminate the main drawback of the classic“ Sputnik V ”- the presence of two components administered to the patient with a difference of several weeks. The Sputnik Light vaccination will require only one visit to the clinic. Immunity will begin to form a week later and will peak four weeks after vaccination. The new drug is based on the same special structures (carrier vectors) as in “Sputnik V”. The vaccine does not contain the coronavirus itself, which means that it will be impossible to get sick with it or infect others, ”said Sergei Sobyanin.

Sputnik Light has already passed the first test phases. Everyone who was injected with it developed immunity to COVID-19. The drug is tolerated by the body like a normal vaccination.

The main stage – international clinical trials – will be attended by six thousand people: three thousand from Russia and the United Arab Emirates.

The Russian part of the research will take place in Moscow at 10 city polyclinics. Any adult citizen can take part in them, provided that he has not previously been vaccinated with “Sputnik V” and has no other contraindications.

Potential test participants will undergo a medical examination. Learn more and sign up for the study at portal.

EDITOR’S NOTE: This article is a translation. Apologies should the grammar and or sentence structure not be perfect.

MIL OSI Russia News